Keranliyan oral liquid for relief of pharyngeal symptoms in COVID-19 convalescent, suspected, and susceptible populations

Phase 4, open-label, single-arm trial of keranliyan in coronavirus disease 2019 (COVID-19) and pharyngitis, sponsored by Maoming People's Hospital. Primary endpoints: Time to relief and relief rate of pharyngeal discomfort symptoms and Time to symptom disappearance or relief for newly developed systemic/respiratory symptoms. Planned start Jun 2020; status: not yet recruiting.